Tag: revenues

Financial and Operating Highlights

[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global Bio Based Propylene Glycol Market size & share revenue was valued at approximately USD 4.53 Billion in 2024 and is expected to reach USD 4.73 Billion in 2025 and is expected to reach around USD 7.03 Billion by 2034, at a CAGR of 4.5% between 2025 and 2034. The key market players listed in the report with their sales, revenues and strategies are Archer Daniels Midland (ADM), BASF SE, Dow Inc., DuPont Tate & Lyle Bio Products, Huntsman International, Cargill Incorporated, Oleon NV, Ashland Global, LyondellBasell Industries, Repsol, SK Global Chemical, P&G Chemicals, Global Bio-Chem Technology Group, ExxonMobil Corporation, Stepan Company, Corbion N.V., Sinopec (China Petroleum & Chemical Corp.), Mitsubishi Chemical Corporation, Shell Chemicals & Others.

NORTH BERGEN, NJ, July 16, 2025 (GLOBE NEWSWIRE) -- Free Flow, Inc. (OTC PK: FFLO), which is incorporated in the state of Delaware as Free Flow USA, Inc., today announced that the Company’s Accurate Investments, Inc subsidiary has entered into a contract to purchase a real estate investment property in New Jersey with existing and arranged highly-accredited tenants that would pay an approximate triple net lease amount of over $1,800,000 per annum against long term leases.

ASHBURN, Va., July 16, 2025 (GLOBE NEWSWIRE) -- Verizon Frontline today announced that two more industry partners have joined the growing list of companies whose products have earned “Verizon Frontline Verified” status. With Radiav and Siyata now part of the "Verizon Frontline Verified" program, Verizon continues to demonstrate its commitment to providing proven 5G-enabled solutions built for first responders.

[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global Ultomiris Drug Market size & share revenue was valued at approximately USD 4.16 Billion in 2024 and is expected to reach USD 5.47 Billion in 2025 and is expected to reach around USD 64.12 Billion by 2034, at a CAGR of 31.52% between 2025 and 2034. The key market players listed in the report with their sales, revenues and strategies are AstraZeneca, Xencor, Inc., Chugai Pharmaceutical, Argenx, Alexion Pharmaceuticals, and others.